BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35387779)

  • 21. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4
    Mancusi A; Piccinelli S; Velardi A; Pierini A
    Front Immunol; 2019; 10():2901. PubMed ID: 31921162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storb RF
    J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
    Sinkovics JG
    Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
    Luznik L; Fuchs EJ
    Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
    Warren EH; Deeg HJ
    Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
    Stevanovic S; van Bergen CA; van Luxemburg-Heijs SA; van der Zouwen B; Jordanova ES; Kruisselbrink AB; van de Meent M; Harskamp JC; Claas FH; Marijt EW; Zwaginga JJ; Halkes CJ; Jedema I; Griffioen M; Falkenburg JH
    Blood; 2013 Sep; 122(11):1963-73. PubMed ID: 23777765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation.
    Ishikawa Y; Kashiwase K; Akaza T; Morishima Y; Inoko H; Sasazuki T; Kodera Y; Juji T
    Bone Marrow Transplant; 2002 Apr; 29(7):569-75. PubMed ID: 11979305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.
    Chopra M; Biehl M; Steinfatt T; Brandl A; Kums J; Amich J; Vaeth M; Kuen J; Holtappels R; Podlech J; Mottok A; Kraus S; Jordán-Garrote AL; Bäuerlein CA; Brede C; Ribechini E; Fick A; Seher A; Polz J; Ottmüller KJ; Baker J; Nishikii H; Ritz M; Mattenheimer K; Schwinn S; Winter T; Schäfer V; Krappmann S; Einsele H; Müller TD; Reddehase MJ; Lutz MB; Männel DN; Berberich-Siebelt F; Wajant H; Beilhack A
    J Exp Med; 2016 Aug; 213(9):1881-900. PubMed ID: 27526711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.